BioCryst Pharmaceuticals Inc

Japan's Ministry of Health, Labour and Welfare approved BioCryst Pharmaceuticals' once-daily ORLADEYO for children with hereditary angioedema aged 2 to 12, making it the first and only oral prophylactic option for pediatric HAE patients in the country. The clearance, announced August 25, expands on the drug's original 2021 Japanese approval for patients 12 and older and extends ORLADEYO's global footprint to more than 45 countries. In the US, where pellet shipments began August 3, prescribers wrote 47 scripts for children within days. BioCryst reported second-quarter revenue of $218.3 million, up 34% year over year, with GAAP operating profit of $98.5 million and $354.0 million in cash, though ORLADEYO net revenue grew just 1% on a reported basis as the total was lifted by $55.7 million from a European navenibart licensing deal. Full-year ORLADEYO guidance stayed at $625 million to $645 million, and Japanese commercial sales must still clear the National Health Insurance pricing process before launch.

BioCryst Pharmaceuticals is looking to acquire more rare disease treatments after reaching consistent profitability on the strength of its hereditary angioedema drug Orladeyo, CEO Charlie Gayer told CNBC on August 28, 2026. Gayer, who took the role in January, said the company expects profits to keep growing every year and does not want to depend on raising outside capital to fund operations. Orladeyo is projected to bring in up to $645 million in 2026 sales. BioCryst has already used its improved financial footing to acquire Astria Therapeutics in January, adding a late-stage hereditary angioedema candidate called navenibart to its pipeline. The company still carries negative shareholders' equity and roughly $822 million in combined term-loan and royalty obligations, and it recorded a $697.8 million non-cash charge tied to acquired in-process research and development from the Astria transaction.

BioCryst Pharmaceuticals reported second quarter 2026 results, with ORLADEYO revenue of $158.2 million, up 10% year-over-year on a comparable basis, and total revenue up 45% year-over-year excluding the European divestiture. The company completed enrollment of its pivotal ALPHA-ORBIT trial for navenibart ahead of schedule, with top-line data expected in the third quarter of 2027. BioCryst also announced it has discontinued internal discovery programs and will close its Birmingham research facility by year-end, shifting to an external innovation model, and raised its full-year total revenue guidance to $690 million to $715 million while maintaining ORLADEYO revenue guidance of $625 million to $645 million. The company ended the quarter with just over $350 million in cash, cash equivalents, and investments, and posted a non-GAAP operating profit of $113.2 million.

BioCryst Pharmaceuticals achieved its first full year of profitability in 2025, with second-quarter 2026 revenue rising 34 percent to 218 million dollars, intensifying acquisition speculation. Takeda ranks as the most plausible acquirer because its HAE injectable Takhzyro is directly threatened by BioCryst's pipeline asset navenibart, while AstraZeneca places second through its Alexion rare-disease platform. The company's oral HAE drug Orladeyo generated 158.2 million dollars in quarterly revenue and carries full-year guidance of 625 million to 645 million dollars, and navenibart's pivotal trial data is expected in the third quarter of 2027. BioCryst closed at 9.84 dollars on August 10, 2026, giving it a market capitalization of roughly 2.5 billion dollars, and analysts hold a consensus price target of 20.82 dollars. No deal talks have been confirmed, and private equity interest is seen as secondary to strategic buyers.

BioCryst Pharmaceuticals raised its full-year 2026 total revenue guidance to a range of $690 million to $715 million, driven by the closing of a navenibart European license agreement. The company maintained its ORLADEYO revenue guidance of $625 million to $645 million and reduced its non-GAAP operating cost guidance to $420 million to $440 million from a prior range of $450 million to $470 million. Second-quarter ORLADEYO revenue reached $158.2 million, contributing to a non-GAAP operating profit of $113.2 million. The company also began shipping ORLADEYO oral pellets for pediatric patients and reported 47 prescriptions through July 31, ahead of full-year expectations. BioCryst ended the quarter with over $350 million in cash, cash equivalents, and investments, and generated positive cash flow even excluding upfront proceeds from the license agreement.